Human herpes virus 8 (HHV8) may be sexually transmitted, but transmission via blood cells has not yet been excluded. We used a modified immunofluorescence assay to detect Ab to HHV8 latency-associated nuclear Ag in sera of 200 allogeneic BMT recipients and their related donors. In control subjects, Ab were found in 85% of patients with AIDS-related Kaposi sarcoma (n = 52), 34% of HIV-1 infected subjects without Kaposi sarcoma (n = 56) and 9.5% of blood donors (n = 42). Among BMT donors, 14.5% were HHV8
Human herpes virus 8 (HHV8) has been linked to several diseases, among which association with classical as well as with AIDS-related Kaposi's sarcoma (KS) appears to be prominent, [1] [2] [3] [4] but it has also been detected in diffuse body cavity-based lymphomas 4 and multicentric Castelman's disease. 5 Sero-epidemiological surveys have confirmed HHV8 prevalence in KS risk groups and its frequency in HIV-1 infected subjects without KS. [6] [7] [8] There is evidence that HHV8 is a sexually transmitted virus which is probably not ubiquitous in the general population, 9, 10 although its geographic seroprevalence is variable, from less than 5% of the general population in Northern Europe and North America to up to 35% in Southern Europe and over 50% in Africa. 6, 8, 9, 11 Beside being found in endothelial and spindle cells of KS lesions, HHV8 DNA has been detected in bone marrow and blood mononuclear cells such as B lymphocytes, monocytes and dendritic cells. [12] [13] [14] [15] This has raised the possibility that HHV8 could be transmitted by blood products or allogeneic BMT, inasmuch as it may be transmitted by a renal transplant. 16 Even though KS has seldom been observed after BMT 17 and only one case of KS possibly transmitted by the donor was found among more than 1500 allogeneic BMTs, 18 BMT recipients could be at risk for HHV8 transmission via the transfusions they receive. Here, we evaluated the possibility of HHV8 transmission by BMT and the possible impact of HHV8 infection on the outcome of allogeneic BMT.
Materials and methods

Sera
Sera from 200 related BMT donor/recipient pairs were chosen on the basis of availability in the serum library of the BMT unit of Hôpital Saint-Louis. Donors were sampled once; recipients were sampled twice: before and 1 year post-BMT or previously in case of death. The main characteristics of the BMT recipients are shown in Table 1 .
Control sera were from 52 patients with AIDS-related KS, 56 HIV-1-infected patients without KS (Pr S Herson, Service de Médecine Interne, Hôpital Pitié-Salpêtrière), and 42 normal blood donors from the Paris area (Dr F Akbalika, Service de Bactério-Virologie, Hôpital Saint-Louis).
All serum samples were stored at р−20°C before being tested.
Cell culture
The BCBL-1 line is a body cavity based B lymphomaderived cell line latently infected by HHV8 and devoid of EBV DNA (NIH AIDS Reagent Program, Rockville, MD, USA). 19 Cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum (Dutscher, Brumath, France), 1% glutamine and 1% antibiotics (Gibco BRL, Paisley, UK), and maintained at 3 × 10 5 cells/ml by dilution with fresh medium every 2 or 3 days. 
Immunofluorescence assay for detecting Ab to latent HHV8 Ag
We used an already reported immunofluorescence serological assay to unstimulated BCBL-1 cells, 20 which detects Ab to HHV8 latency-associated nuclear Ag (LANA), with some modifications: sera were diluted 1:150, and the reaction was revealed with a peroxydase-labeled anti-human IgG rabbit antiserum (Dako, Glostrup, Denmark) diluted 1:100, followed by biotinyl tyramide amplification according to the manufacturer's instructions (NEN Life Science Products, Boston, MA, USA) and development with FITCStreptavidin (Dako). Slides were mounted with a fluorescent mounting medium (Dako), and visualized by immunofluorescence microscopy at ×200 magnification. Positivity was defined as clearcut nuclear fluorescence.
Statistics
Statistical analyses of the differences between groups were performed using the 2 test for independent or paired samples, or the log-rank test, as requested.
Results
Control sera
In line with other reports, 8, 9, 11, [20] [21] [22] 85% of sera from patients (44/52) with AIDS-related KS were HHV8 ϩ . Sera from 1 to 5 years before diagnosis were already HHV8 ϩ in 20/21 patients for whom pre-KS samples were available; in one case HHV8 positivity was found only 3 months before KS. Irrespective of the clinical stage, 34% of HIV- ϩ .
BMT donors and recipients
Donors and recipients were not representative of the Paris population, inasmuch as the Saint-Louis BMT program enrolls patients from different parts of France and Europe. However, related donors and recipients were obviously matched for many parameters -ethnic and geographic origin, for example -with differences relating mainly to the recipient's disease and blood transfusion history. In addition, BMT recipients and donors did not differ significantly with respect to age or gender (data not shown), and no KS was diagnosed in either population. Sera of 14.5% of donors were HHV8 ϩ , 83.5% were negative and 2% had indeterminate reactivity (Table 2 . Before BMT, 10% of recipients were HHV8 ϩ , 88% were negative and 2% were indeterminate (Table 2 ). HHV8 seroprevalence in donors and recipients was not significantly different (P = 0.17), and neither was different from that in the control blood donor group (P = 0.39 and P = 0.92, respectively).
After BMT, the proportion of HHV8 seropositive recipients increased to 18% (Tables 1 and 2 ). Of the 176 recipients who were initially HHV8 − , 148 remained negative and 26 (15%) seroconverted, but a greater proportion (50%) of the 20 initially HHV8 ϩ recipients seroreverted (P Ͻ 0.01). Seroconversion occurred in 12% (20/167) of recipients of HHV8 − BMT vs 20.5% (6/29) when the BMT donor was HHV8 ϩ (Table 2 ), which was not statistically different (P = 0.20).
Finally, the influence of HHV8 infection on BMT outcome was assessed by analyzing recipients according to their pre-and post-BMT HHV8 status irrespective of that of the donors. No relationship could thus be found between HHV8 serology and the recipients' age at time of BMT, HLA matching, diagnosis at entry and engraftment (Table 1) . Similarly, HHV8 seropositivity did not influence the occurrence of acute GVHD or that of subsequent chronic GVHD, nor the overall BMT survival (Figure 1 ).
Discussion
We examined 200 BMT donor/recipient pairs for the risk of HHV8 transmission at BMT, using an already described assay that detect Ab to LANA 20, 23 that was modified so as to increase its sensitivity. BMT recipients are highly transfused, and they may thus be at risk of HHV8 infection by blood transfusions or by the transplant, 24, 25 inasmuch as HHV8 DNA has been detected in blood mononuclear cells of apparently healthy individuals. AIDS-related KS, HIV-1 ϩ patients and blood donors were tested as controls. As reported, 21 85% of KS patients had Ab to LANA, whereas 34% HIV ϩ patients without KS were positive. 6, 8, 9 HHV8 seroprevalence in France seems to be comparable to that in Mediterranean countries and higher than in Northern Europe, 24, 25 and HHV8 seropositivy among blood donors from the Paris area was indeed comparable (around 10%) to that of the BMT donors and recipients before BMT, some of whom originated from Italy and North Africa and were thus not representative of the French population. In addition, these data indicate that BMT recipients had apparently not been at greater risk than their donors of being contaminated by HHV8 before BMT and, interestingly, no significant difference in the proportion of HHV8 ϩ recipients was found according to their age (see Table 1 ). However, seropositivity and current active infection should not be considered as synonymous, and it cannot be ruled out that some of the patients had actually been exposed to HHV8 but failed to mount an Ab response. 26 Nevertheless, the possibility of HHV8 transmission by BMT was then evaluated taking into account donor and recipient HHV8 serological status. We found 23 seronegative recipients who received a BMT from a positive donor, and 149 donor/recipient pairs where both were negative. Assaying post-BMT sera did not disclose more seroconversion in the first group than in the second, which indicates that post-BMT HHV8 serology is not influenced by donor HHV8 positivity and that seroconversion among HHV8 − recipients is not linked to BMT per se. Thus, although the risk of HHV8 transmission by the BMT donor is low, risk of being infected after BMT exists, presumably in relation to blood transfusions received then. Most studies suggest that the probability of transmitting HHV8 by blood products should be very low, and KS is rare in patients infected by HIV via transfusion. [27] [28] [29] Nevertheless, this possibility cannot be excluded, and our data raise the question of whether screening blood donations for HHV8 is necessary.
HHV8 DNA has been found in BM cells of multiple myeloma and of Waldenstrom's macroglobulinemia patients. 13, 14, 26, [30] [31] [32] [33] These patients are not common candidates for allogeneic BMT, and they were not represented among the BMT recipients studied here. We did not find any relation between HHV8 infection and any of the wide variety of hematological diseases noted in this group of BMT recipients. The latent infection of our patients might predispose them to late complications, including disorders of the immune system, but long-term follow-up of the recipients allowed exclusion of this possibility at least with respect to occurrence of chronic GVHD and overall BMT survival. In conclusion, these data indicate that, if post-BMT infection with HHV8 occurs, patients are probably contaminated by blood transfusions rather than by BMT donors. However, no KS was observed in the HHV8 ϩ recipients investigated here, and it appears that HHV8 prior seropositivity, seroconversion or seroreversion is not linked to the outcome of BMT. The lack of HHV8-associated diseases in this immunosuppressed population might suggest that occurrence of such diseases involves secondary mechanisms presumably linked to the continued activation of HHV8 genes.
